Tasaka Shun, Jingu Keiichi, Takahashi Noriyoshi, Umezawa Rei, Yamamoto Takaya, Ishikawa Yojiro, Takeda Kazuya, Suzuki Yu, Kadoya Noriyuki
Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Front Oncol. 2021 May 7;11:665837. doi: 10.3389/fonc.2021.665837. eCollection 2021.
Xerostomia is one of the most common adverse events of radiotherapy in head and neck cancer patients. There have been many reports on functional changes of the parotid gland after radiation therapy, but there have been few reports on the volume of the parotid gland and its relationship with oral quality of life (QOL) and even fewer reports on longitudinal change of the parotid gland volume. The purpose of this study was to evaluate the long-term change of the parotid gland volume after intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma and the relationship between parotid irradiation dose and xerostomia symptoms.
We retrospectively analyzed 26 patients with nasopharyngeal cancer treated by IMRT. Longitudinal changes of parotid gland volumes after IMRT were evaluated on CT images. The parotid gland volumes in each period were converted to the ratio to parotid gland volumes before radiotherapy (relative parotid volume). Dunnett's test was used to evaluate the longitudinal changes in relative parotid volumes at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT. We assessed xerostomia 3 years or more after IMRT by measuring the degree of oral moisture using a moisture-checking device (Mucus, Life Co., Ltd.) and oral QOL evaluation by GOHAI (General Oral Health Assessment Index).
The relative parotid volumes during radiotherapy and at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT were 75.2 ± 14.3%, 67.2 ± 11.4%, 68.5 ± 15.9%, 72.4 ± 14.8%, 73.0 ± 13.8%, 76.2 ± 17.5%, and 77.1% ± 17.3%, respectively. The parotid volume had recovered significantly at 43-54 and 55-66 months after IMRT, especially in parotids receiving less than 40 Gy as the mean dose. The mean irradiated dose for bilateral parotids showed negative correlations with oral QOL score and oral moisture after a long period.
The parotid volume recovered gradually but had not reached a plateau even 3 years after radiotherapy, especially in parotids receiving less than 40 Gy as the mean dose.
口干是头颈癌患者放疗最常见的不良事件之一。关于放疗后腮腺功能变化的报道很多,但关于腮腺体积及其与口腔生活质量(QOL)关系的报道较少,关于腮腺体积纵向变化的报道更少。本研究的目的是评估鼻咽癌调强放疗(IMRT)后腮腺体积的长期变化以及腮腺照射剂量与口干症状之间的关系。
我们回顾性分析了26例接受IMRT治疗的鼻咽癌患者。在CT图像上评估IMRT后腮腺体积的纵向变化。将各时期的腮腺体积转换为放疗前腮腺体积的比值(相对腮腺体积)。采用Dunnett检验评估IMRT后0-6、7-18、19-30、31-42、43-54和55-66个月相对腮腺体积的纵向变化。我们通过使用水分检测装置(Mucus,Life Co., Ltd.)测量口腔湿度以及采用GOHAI(一般口腔健康评估指数)评估口腔QOL,来评估IMRT后3年或更长时间的口干情况。
放疗期间以及IMRT后0-6、7-18、19-30、31-42、43-54和55-66个月的相对腮腺体积分别为75.2±14.3%、67.2±11.4%、68.5±15.9%、72.4±14.8%、73.0±13.8%、76.2±17.5%和77.1%±17.3%。IMRT后43-54和55-66个月时腮腺体积显著恢复,尤其是平均剂量小于40 Gy的腮腺。双侧腮腺的平均照射剂量与长期后的口腔QOL评分和口腔湿度呈负相关。
腮腺体积逐渐恢复,但即使放疗后3年仍未达到平台期,尤其是平均剂量小于40 Gy的腮腺。